Loading...
•
Jun 30, 2024
Invivyd Q2 2024 Earnings Report
Invivyd reported financial results for Q2 2024, launched PEMGARDA commercially with $2.3 million in net product revenue, and achieved Medicare and Medicaid coverage.
Key Takeaways
Invivyd launched PEMGARDA commercially in Q2 2024, generating $2.3 million in net product revenue. The company ended the quarter with $147.9 million in cash and cash equivalents and is preparing for the peak fall/winter respiratory virus season.
PEMGARDA launched commercially in Q2 2024 with $2.3 million of net product revenue.
Commercial results accelerated in early Q3 2024.
New commercial leadership was appointed with Tim Lee as Chief Commercial Officer.
Cash and cash equivalents totaled $147.9 million at the end of Q2 2024.
Revenue by Segment
Forward Guidance
Invivyd anticipates 2024 net product revenue of $150 million to $200 million and expects to end 2024 with at least $75 million in cash and cash equivalents, based on current operating plans and recent resource realignment.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...